Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Rheonix, BioFire Diagnostics Name New Board Members

Premium

Rheonix has named Bill Colston to its board of directors, the company said this week.

Colston is the former CEO of QuantaLife, which was acquired by Bio-Rad Laboratories in 2011. As QuantaLife CEO, Colston grew the company from four founders in 2008 to more than 60 employees by 2011. Before founding QuantaLife in 2008, Colston had a 19-year career at Lawrence Livermore National Laboratory, advancing from scientist to program manager directing a $160 million annual budget and 400 employees.

He holds a BS from the University of Texas, Austin and a PhD in biomedical engineering from the University of California, Davis.

Rheonix, based in Ithaca, NY, is developing fully automated, cartridge-based molecular testing platform.


BioFire Diagnostics said this week that it has appointed Herm Rosenman to its board of directors and chairman of the audit committee.

Rosenman was senior vice president and CFO of Gen-Probe from 2001 until its recent acquisition by Hologic. Prior to joining Gen-Probe, Rosenman served as CEO of two Nasdaq-listed companies, served on the boards of multiple healthcare companies, and was a partner at Coopers & Lybrand (now PricewaterhouseCoopers). Rosenman is a CPA, received a BBA in finance and accounting from Pace University, and an MBA in finance from the Wharton School of the University of Pennsylvania.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.